secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2026-06-11T20:28:37+00:00
Accession:  0001193125-26-267640
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 3.03, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jade Biosciences stockholder meeting approves jury trial waiver and adopts amended bylaws
--------------------------------------------------------------------------------

- Class II directors Christopher Cain (34.4M for) and Tom Frohlich (42.4M for) elected.
- PricewaterhouseCoopers ratified as independent auditor for FY2026 (46.0M for).
- Amendment to Articles waiving jury trials in certain circumstances approved (39.9M for).
- Board adopted amended bylaws to align with Nevada law, including virtual meetings and updated voting standards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000119312526267640/0001193125-26-267640-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000119312526267640/d161530d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-267640

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer